

Special Issue

Novel Therapeutic Classes in Lung Cancer

Message from the Guest Editors

Lung cancer remains the leading cause of cancer-related mortality worldwide despite substantial progress in molecularly targeted therapies and immunotherapy. The therapeutic landscape continues to evolve rapidly with the development of novel therapeutic classes, innovative combination strategies and emerging treatment paradigms that have the potential to further improve outcomes across lung cancer.

This Special Issue aims to provide a comprehensive and contemporary overview of emerging therapeutic advances in lung cancer, spanning basic, translational and clinical research. We welcome original research articles, state of the art reviews and perspective pieces addressing new drug classes, rational combination strategies, resistance mechanisms, biomarker development, precision oncology approaches and real-world implementation challenges.

In addition to currently established and emerging therapeutic modalities, we encourage submissions exploring innovative treatment concepts, novel biological pathways and future therapeutic platforms that may shape the next generation of lung cancer care. This Special Issue welcomes reviews as well as articles by 31st December 2026.

Guest Editors

Dr. Rajat Thawani

Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Dr. Rohit Singh

Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA

Deadline for manuscript submissions

31 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/278028

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)